AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 36187849 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Eating for Successful Living in Older Adults™ program
Number of subjects: 0
Study 36187849 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 36187926 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical exome sequencing and collapsing analyses for genetic variants in ARDS samples.
Number of subjects: 515
Study 36187926 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-ARDS neonates)
Number of subjects: 515
Study 36188162 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI) telehealth intervention protocol (PREPaRe)
Number of subjects: 0
Study 36188162 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 36188406 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA + EPA supplementation (2.442 g/day DHA and 1.020 g/day EPA)
Number of subjects: 38
Study 36188406 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 36188406 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA + EPA supplementation
Number of subjects: 38
Study 36188434 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregivers of patients with ECD and other HN
Number of subjects: 0
Study 36188763 — intervention group
Group type: EXPERIMENTAL
Intervention: Sub-maximal exercise
Number of subjects: 0
Study 36188763 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 36188784 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone-based symptom monitoring
Number of subjects: 0
Study 36188867 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetitive Transcranial Magnetic Stimulation (rTMS) combined with Video Game-Based Training, details on dosage and duration not available
Number of subjects: 0
Study 36188867 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified, details not available
Number of subjects: 0
Study 36188922 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic upper extremity rehabilitation combined with motor cortex anodal tDCS
Number of subjects: 8
Study 36188946 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional Electrical Stimulation (FES) therapy delivered by the MyndMove stimulator, 40 sessions
Number of subjects: 51
Study 36188946 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 51
Study 36189008 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-min slow diaphragmatic breathing for 5 weeks, three times/week, with breath science education once/week
Number of subjects: 43
Study 36189008 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual control
Number of subjects: 43
Study 36189008 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-min slow diaphragmatic breathing for 5 weeks
Number of subjects: 43
Study 36189036 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized practice dosages
Number of subjects: 0
Study 36189036 — intervention group
Group type: COMPARATOR
Intervention: Standard of care practice dosages
Number of subjects: 0
Study 36189037 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength training (low-intensity, moderate-intensity, high-intensity based on MEPs) 3X/week for 4 weeks
Number of subjects: 90
Study 36189037 — intervention group
Group type: EXPERIMENTAL
Intervention: Real anodal tDCS (2 mA, 20 min)
Number of subjects: 90
Study 36189037 — intervention group
Group type: COMPARATOR
Intervention: Sham anodal tDCS (2 mA, 20 min)
Number of subjects: 90
Study 36189149 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg hydroxyzine plus 0.5 mg/kg midazolam
Number of subjects: 45
Study 36189149 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg/kg hydroxyzine plus 0.5 mg/kg midazolam
Number of subjects: 45
Study 36189149 — intervention group
Group type: COMPARATOR
Intervention: 0.5 mg/kg midazolam alone
Number of subjects: 45
Study 36189181 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxious depression with no pain
Number of subjects: 158
Study 36189181 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxious depression with mild to moderate pain
Number of subjects: 158
Study 36189181 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxious depression with severe pain
Number of subjects: 158
Study 36189181 — intervention group
Group type: EXPERIMENTAL
Intervention: Atypical depression in remission
Number of subjects: 158
Study 36189196 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk PCI with VA-ECMO support
Number of subjects: 14
Study 36189333 — intervention group
Group type: EXPERIMENTAL
Intervention: Below elbow cast (BEC)
Number of subjects: 280
Study 36189333 — intervention group
Group type: COMPARATOR
Intervention: Above elbow cast (AEC)
Number of subjects: 280
Study 36189333 — intervention group
Group type: COMPARATOR
Intervention: Comparison of BEC and AEC
Number of subjects: 280
Study 36189636 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapivirine vaginal ring (DVR)
Number of subjects: 151
Study 36189636 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 151
Study 36189747 — intervention group
Group type: EXPERIMENTAL
Intervention: Psoriasis patients with metabolic disorders
Number of subjects: 920
Study 36189747 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 920
Study 36189908 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary dental care (PDC) treatment
Number of subjects: 52
Study 36189908 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 52
Study 36190432 — intervention group
Group type: EXPERIMENTAL
Intervention: siHIF2
Number of subjects: 1
Study 36190432 — intervention group
Group type: EXPERIMENTAL
Intervention: PT2399
Number of subjects: 1
Study 36190480 — intervention group
Group type: EXPERIMENTAL
Intervention: Empowering leadership training, direct field experimentation of empowering leadership, and coaching for 12 months.
Number of subjects: 751
Study 36190480 — intervention group
Group type: COMPARATOR
Intervention: Control sub-centre without intervention.
Number of subjects: 751
Study 36190503 — intervention group
Group type: EXPERIMENTAL
Intervention: Impact-induced injuries
Number of subjects: 214
Study 36190503 — intervention group
Group type: EXPERIMENTAL
Intervention: Back injuries
Number of subjects: 214
Study 36190503 — intervention group
Group type: EXPERIMENTAL
Intervention: Neck injuries
Number of subjects: 214
Study 36190503 — intervention group
Group type: EXPERIMENTAL
Intervention: Loss of consciousness
Number of subjects: 214
Study 36190503 — intervention group
Group type: EXPERIMENTAL
Intervention: Impaired capacity to perform job
Number of subjects: 214
Study 36190503 — intervention group
Group type: EXPERIMENTAL
Intervention: Sick leave
Number of subjects: 214
Study 36190503 — intervention group
Group type: EXPERIMENTAL
Intervention: Veterans Affairs disability rating
Number of subjects: 214
Study 36190503 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery during active duty
Number of subjects: 214
Study 36190503 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery after leaving active service
Number of subjects: 214
Study 36190522 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant pembrolizumab
Number of subjects: 155
Study 36190737 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral paracetamol 1000 mg × 4 + oral ibuprofen 400 mg × 4 + intravenous placebo
Number of subjects: 1060
Study 36190737 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral paracetamol 1000 mg × 4 + intravenous dexamethasone 24 mg + oral placebo
Number of subjects: 1060
Study 36190737 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ibuprofen 400 mg × 4 + intravenous dexamethasone 24 mg + oral placebo
Number of subjects: 1060
Study 36190737 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral paracetamol 1000 mg × 4 + oral ibuprofen 400 mg × 4 + intravenous dexamethasone 24 mg
Number of subjects: 1060
Study 36190737 — intervention group
Group type: COMPARATOR
Intervention: Placebo (oral and intravenous)
Number of subjects: 1060
Study 36190744 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronolife smart t-shirt worn daily for 2 weeks (preferably 8 hours per day)
Number of subjects: 20
Study 36190739 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 1388
Study 36190739 — intervention group
Group type: EXPERIMENTAL
Intervention: H2 antagonists (nizatidine, famotidine, ranitidine)
Number of subjects: 1388
Study 36190739 — intervention group
Group type: EXPERIMENTAL
Intervention: Monoamine modulators (reboxetine, fluoxetine)
Number of subjects: 1388
Study 36190739 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate
Number of subjects: 1388
Study 36190739 — intervention group
Group type: COMPARATOR
Intervention: Placebo or no treatment (standard care)
Number of subjects: 1388
Study 36190739 — intervention group
Group type: COMPARATOR
Intervention: All agents
Number of subjects: 1388
Study 36190762 — intervention group
Group type: EXPERIMENTAL
Intervention: Proteinuria
Number of subjects: 576
Study 36190762 — intervention group
Group type: COMPARATOR
Intervention: Control (no proteinuria)
Number of subjects: 576
Study 36190843 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline eHealth literacy assessment using eHealth Literacy Scale (eHEALS)
Number of subjects: 1970
Study 36190843 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline eHealth literacy
Number of subjects: 1970
Study 36190843 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-month follow-up eHealth literacy
Number of subjects: 1970
Study 36191284 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Number of subjects: 907
Study 36191284 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Number of subjects: 907
Study 36191284 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole
Number of subjects: 907
Study 36191836 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe pain
Number of subjects: 488
Study 36191836 — intervention group
Group type: EXPERIMENTAL
Intervention: Constant pain
Number of subjects: 488
Study 36191836 — intervention group
Group type: COMPARATOR
Intervention: No pain
Number of subjects: 488
Study 36191836 — intervention group
Group type: COMPARATOR
Intervention: Mild-moderate pain
Number of subjects: 488
Study 36192219 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane (dose not specified)
Number of subjects: 167
Study 36192231 — intervention group
Group type: EXPERIMENTAL
Intervention: Ovulation Induction (OI) or No Treatment
Number of subjects: 2369
Study 36192231 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrauterine Insemination (IUI)
Number of subjects: 2369
Study 36192231 — intervention group
Group type: EXPERIMENTAL
Intervention: In Vitro Fertilization (IVF)
Number of subjects: 2369
Study 36192237 — intervention group
Group type: EXPERIMENTAL
Intervention: Prexasertib (LY2606368)
Number of subjects: 169
Study 36192280 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorsal Root Ganglion Stimulation (DRGS)
Number of subjects: 9
Study 36192386 — intervention group
Group type: EXPERIMENTAL
Intervention: Sinovac-CoronaVac vaccine
Number of subjects: 0
Study 36192514 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination intra-peritoneal and systemic chemotherapy
Number of subjects: 0
Study 36192569 — intervention group
Group type: EXPERIMENTAL
Intervention: Prone positioning with bedside titrated PEEP
Number of subjects: 0
Study 36192569 — intervention group
Group type: COMPARATOR
Intervention: Supine positioning with bedside titrated PEEP
Number of subjects: 0
Study 36192606 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood flow restriction - low load strength training (BFR-LLST) added to usual care exercise
Number of subjects: 42
Study 36192802 — intervention group
Group type: EXPERIMENTAL
Intervention: Financial navigation (FN) intervention
Number of subjects: 780
Study 36192847 — intervention group
Group type: EXPERIMENTAL
Intervention: octocog alfa (Kovaltry®/BAY 81-8973) prophylaxis regimen
Number of subjects: 302
Study 36193630 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical atherothrombectomy
Number of subjects: 0
Study 36193749 — intervention group
Group type: EXPERIMENTAL
Intervention: Preexisting cardiovascular disease (CVD)
Number of subjects: 5133
Study 36193749 — intervention group
Group type: EXPERIMENTAL
Intervention: Myocardial injury on ICU admission
Number of subjects: 5133
Study 36193749 — intervention group
Group type: COMPARATOR
Intervention: No preexisting CVD
Number of subjects: 5133
Study 36194207 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-in-1 score
Number of subjects: 26
Study 36194207 — intervention group
Group type: EXPERIMENTAL
Intervention: Parents' recognition of initial manifestations
Number of subjects: 26
Study 36194207 — intervention group
Group type: EXPERIMENTAL
Intervention: Physicians' recognition of initial manifestations
Number of subjects: 26
Study 36194207 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnostic delay
Number of subjects: 26
Study 36194207 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenotypical characterization
Number of subjects: 26
Study 36194207 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurologic outcomes
Number of subjects: 26
Study 36194251 — intervention group
Group type: EXPERIMENTAL
Intervention: Gluten-free diet (GFD)
Number of subjects: 45
Study 36194251 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 45
Study 36194306 — intervention group
Group type: EXPERIMENTAL
Intervention: Venatech® retrievable IVC filter
Number of subjects: 40
Study 36194312 — intervention group
Group type: EXPERIMENTAL
Intervention: Stakeholder and Equity Data-Driven Implementation (SEDDI) process
Number of subjects: 4
Study 36194312 — intervention group
Group type: EXPERIMENTAL
Intervention: Cultural, linguistic, and health literacy tailoring adaptations
Number of subjects: 4
Study 36194312 — intervention group
Group type: EXPERIMENTAL
Intervention: Facilitation sessions
Number of subjects: 4
Study 36194312 — intervention group
Group type: EXPERIMENTAL
Intervention: SEDDI
Number of subjects: 4
Study 36194312 — intervention group
Group type: COMPARATOR
Intervention: None (control group not explicitly mentioned)
Number of subjects: 4
Study 36194420 — intervention group
Group type: EXPERIMENTAL
Intervention: Scaling and root planning plus amoxicillin and metronidazole
Number of subjects: 468
Study 36194420 — intervention group
Group type: EXPERIMENTAL
Intervention: Scaling and root planning plus oral hygiene instruction
Number of subjects: 468
Study 36194420 — intervention group
Group type: COMPARATOR
Intervention: Supragingival scaling
Number of subjects: 468
Study 36194420 — intervention group
Group type: COMPARATOR
Intervention: Oral hygiene instruction plus a copy of radiographs and recommendation to follow-up with a dentist
Number of subjects: 468
Study 36194458 — intervention group
Group type: EXPERIMENTAL
Intervention: REST video-delivered family therapeutic intervention
Number of subjects: 106
Study 36194473 — intervention group
Group type: EXPERIMENTAL
Intervention: ECMO during the first wave
Number of subjects: 54
Study 36194473 — intervention group
Group type: EXPERIMENTAL
Intervention: ECMO during the second wave
Number of subjects: 54
Study 36194473 — intervention group
Group type: EXPERIMENTAL
Intervention: ECMO during the third wave
Number of subjects: 54
Study 36194473 — intervention group
Group type: EXPERIMENTAL
Intervention: Time from symptoms onset to ECMO
Number of subjects: 54
Study 36194473 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in CARDS management from first to second wave
Number of subjects: 54
Study 36194483 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 11
Study 36194483 — intervention group
Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 11
Study 36194670 — intervention group
Group type: EXPERIMENTAL
Intervention: Camrelizumab (CC)
Number of subjects: 0
Study 36194670 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (CA)
Number of subjects: 0
Study 36194864 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose multiplayer virtual reality telegaming program (2 supervised 1-hour sessions per week for 1 month)
Number of subjects: 12
Study 36194890 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial interventions for sexual abuse and violence
Number of subjects: 37
Study 36195441 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infliximab (IFX) 3 mg/kg
Number of subjects: 225
Study 36195441 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo (PLBO)
Number of subjects: 225
Study 36195441 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infliximab (IFX)
Number of subjects: 225
Study 36195591 — intervention group
Group type: EXPERIMENTAL
Intervention: Maltreatment (measured by Childhood Trauma questionnaire and Adverse Childhood Experiences questionnaire)
Number of subjects: 82
Study 36195591 — intervention group
Group type: EXPERIMENTAL
Intervention: Household Dysfunction
Number of subjects: 82
Study 36195836 — intervention group
Group type: EXPERIMENTAL
Intervention: High EVI1 expression in TNBC patients
Number of subjects: 993
Study 36195993 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrate treatment
Number of subjects: 182
Study 36195993 — intervention group
Group type: EXPERIMENTAL
Intervention: CAD-HF patients with PH
Number of subjects: 182
Study 36195993 — intervention group
Group type: EXPERIMENTAL
Intervention: HFrEF-PH patients
Number of subjects: 182
Study 36195993 — intervention group
Group type: EXPERIMENTAL
Intervention: CAD-HF patients with enlarged left ventricular end-diastolic diameter and reduced hemoglobin
Number of subjects: 182
Study 36195993 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated creatinine and mean pulmonary arterial pressure (mPAP), diastolic pressure gradient (DPG) ≥7 mmHg, and previous myocardial infarction (MI)
Number of subjects: 182
Study 36196048 — intervention group
Group type: EXPERIMENTAL
Intervention: Gene therapy-based clinical trials (NCT04693598 and NCT04771416) for Krabbe disease
Number of subjects: 0
Study 36196060 — intervention group
Group type: EXPERIMENTAL
Intervention: Time-to-diuretics (intravenous furosemide) administered within the first 24 hours, median time 67 minutes (25th-75th percentiles 17-190 minutes)
Number of subjects: 15078
Study 36196060 — intervention group
Group type: EXPERIMENTAL
Intervention: Time-to-diuretics administered between hospital arrival and 8 hours post-hospital arrival
Number of subjects: 15078
Study 36196609 — intervention group
Group type: EXPERIMENTAL
Intervention: BNT162b2 mRNA COVID-19 vaccine
Number of subjects: 51
Study 36196777 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenfluramine (0.2 mg/kg/day, titrated by effectiveness and tolerability)
Number of subjects: 247
Study 36196777 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenfluramine
Number of subjects: 247
Study 36196899 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized morphine (nMOR) 10 mg
Number of subjects: 75
Study 36196899 — intervention group
Group type: EXPERIMENTAL
Intervention: nMOR
Number of subjects: 75
Study 36197049 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-17 expression in perifollicular fibrosis in LPP
Number of subjects: 40
Study 36197049 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-17 expression in lichenoid inflammatory infiltrate in LPP
Number of subjects: 40
Study 36197049 — intervention group
Group type: COMPARATOR
Intervention: Chronic telogen effluvium biopsies
Number of subjects: 40
Study 36197159 — intervention group
Group type: EXPERIMENTAL
Intervention: Participation group
Number of subjects: 1804
Study 36197159 — intervention group
Group type: COMPARATOR
Intervention: Nonparticipation group
Number of subjects: 1804
Study 36197507 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-scan imaging
Number of subjects: 2380
Study 36197507 — intervention group
Group type: COMPARATOR
Intervention: Other diagnostics
Number of subjects: 2380
Study 36197507 — intervention group
Group type: EXPERIMENTAL
Intervention: Radical nephroureterectomy
Number of subjects: 2380
Study 36197536 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant endocrine therapy
Number of subjects: 300
Study 36197536 — intervention group
Group type: EXPERIMENTAL
Intervention: Worsening endocrine symptoms
Number of subjects: 300
Study 36197536 — intervention group
Group type: EXPERIMENTAL
Intervention: Worsening physical function
Number of subjects: 300
Study 36197536 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior mastectomy
Number of subjects: 300
Study 36197661 — intervention group
Group type: EXPERIMENTAL
Intervention: Apremilast 30 mg orally twice daily
Number of subjects: 8
Study 36197682 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant intensity-modulated radiotherapy (IMRT) followed by hepatectomy
Number of subjects: 38
Study 36197706 — intervention group
Group type: COMPARATOR
Intervention: Bolstered usual care (literature on antiretroviral therapy adherence promotion and stigma reduction)
Number of subjects: 840
Study 36197706 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple family groups for HIV stigma reduction plus family economic empowerment (MFG-HIVSR plus FEE)
Number of subjects: 840
Study 36197706 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based HIV stigma reduction for educators (GED-HIVSR)
Number of subjects: 840
Study 36197809 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrograde intramedullary nail (RIMN)
Number of subjects: 753
Study 36197809 — intervention group
Group type: COMPARATOR
Intervention: Locking plates
Number of subjects: 753
Study 36198179 — intervention group
Group type: EXPERIMENTAL
Intervention: IVIG (2.0 g/kg every 4 weeks for 16 weeks)
Number of subjects: 95
Study 36198179 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95
Study 36198473 — intervention group
Group type: EXPERIMENTAL
Intervention: PRPP intervention (9 sessions)
Number of subjects: 6
Study 36198473 — intervention group
Group type: COMPARATOR
Intervention: Delayed intervention phases
Number of subjects: 6
Study 36198473 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal Attainment Scaling and Barthel Index
Number of subjects: 6
Study 36198471 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine learning (ML) algorithm for reading WB-MRI scans
Number of subjects: 633
Study 36198471 — intervention group
Group type: EXPERIMENTAL
Intervention: ML-assisted reading
Number of subjects: 633
Study 36198471 — intervention group
Group type: EXPERIMENTAL
Intervention: Experienced readers with ML
Number of subjects: 633
Study 36198471 — intervention group
Group type: COMPARATOR
Intervention: Experienced readers without ML
Number of subjects: 633
Study 36198565 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiolabeled peptide pair
Number of subjects: 0